



[Fig. 1]



[Fig. 2]


A type (Heterodimer, 1+1, asymmetric)	B type (Homodimer, symmetric, N-term)	C type (Homodimer, symmetric, C-term)	Control monoclonal Ab	
 A-ME	 B-ME	 C-ME	 EGFR-Ab (Positive Control)	 EGFR targeting Ab (VHH) TNFα targeting Ab (VHH) APLP2 targeting Ab (Fab) M6PR targeting Ab (Fab)
 A-MT	 B-MT	 C-MT	 M6PR Ab	
 A-AE	 B-AE	 C-AE	 TNFα-Ab (Negative Control)	
 A-AT	 B-AT	 C-AT	 APLP2 Ab	

[Fig. 3]




[Fig. 4]


[Cell surface EGFR internalization]




[Fig. 5]




[Fig. 6]




[Clone selection]




[Fig. 8]




[Fig. 9]




[Fig. 10]




[Fig. 11]

Lysosome-dependent EGFR degradation of M6PR-Lportbody

[Fig. 12]




[Fig. 13]




- Ab1 = Ab2 ; self-binding
 ■ Overlapping of binding site of Ab1 and Ab2
 ■ Non-overlapping of binding site of Ab1 and Ab2
 ■ Uni-direction


[Bin-chart]




[Fig. 14a]




[Fig. 14b]




[Fig. 15]




[Fig. 16]




[Fig. 17]



[Fig. 18]



[Fig. 19]



[Fig. 20]

